Jefferies raised the firm’s price target on Abbott (ABT) to $137 from $135 and keeps a Hold rating on the shares after the company reported “solid” Q1 results and reaffirmed FY25 guidance despite tariffs. While the firm remains Hold rated on the shares, the analyst was “impressed by the result” and Abbott’s ability to navigate tariffs and macro pressure.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- Nvidia, AMD see charges due to new China export rules: Morning Buzz
- Abbott Laboratories: Strong Organic Growth and Strategic Positioning Drive ‘Buy’ Rating
- Abbott price target raised to $140 from $138 at Evercore ISI
- Early notable gainers among liquid option names on April 16th
- Abbott says seeing growth in Diagnostics unit everywhere except China